title: Prognostic value of electromyography in acute peripheral facial nerve palsy.
abstract: OBJECTIVE
  To analyze the value of electromyography in predicting recovery from acute idiopathic facial nerve paralysis.
  
  
  METHODS
  Retrospective case-series review.
  
  
  METHODS
  University-based hospital department of otorhinolaryngology/head neck surgery.
  
  
  METHODS
  Three hundred fifty-five patients with sudden facial paralysis of unknown cause (Bell's palsy).
  
  
  METHODS
  Treatment consisted uniformly of high-dose prednisolone, dextran, and pentoxifylline. Prognostication was based on electromyography performed not earlier than 10 to 14 days after the onset of palsy. The findings were classified according to Seddon into neurapraxia and axonotmesis/ neurotmesis. There is an inherent statement on prognosis in this classification because neurapraxia is presumed to recover completely within 8 to 12 weeks, whereas axonotmesis is most likely to be followed by sequelae.
  
  
  METHODS
  Facial nerve function after 6 months.
  
  
  RESULTS
  Complete recovery was predicted correctly in 92.4% of cases. For the relatively rare and therefore principally more difficult predictable event defective recovery prognosis was still accurate in 80.8%.
  
  
  CONCLUSIONS
  The detection of spontaneous fibrillation in needle electromyography is a reliable sign predicting unfavorable outcome. An accuracy of 80.8% for predicting unfavorable outcome may be sufficient to advise patients what to expect in the course of their facial nerve disorder. However, it seems dubious to build a decision about surgical intervention on such a test, because in the process, unnecessary surgery would be accepted for as much as one fifth of the patient population.
authors: Department of Otorhinolaryngology/Head Neck Surgery, University of Cologne, Germany.
authors: C
authors: C
authors: Sittel
authors: E
authors: E
authors: Stennert
mesh_terms: D000208:Acute Disease; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D003911:Dextrans / Q000627:therapeutic use; D004576:Electromyography / Q000379:methods; D005152:Facial Muscles / Q000294:innervation / Q000503:physiopathology; D005154:Facial Nerve / Q000503:physiopathology; D005158:Facial Paralysis / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D006401:Hematologic Agents / Q000627:therapeutic use; D006801:Humans; D009046:Motor Neurons / Q000502:physiology; D009431:Neural Conduction / Q000502:physiology; D010431:Pentoxifylline / Q000627:therapeutic use; D011237:Predictive Value of Tests; D011239:Prednisolone / Q000627:therapeutic use; D012189:Retrospective Studies
chemical_list: D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D003911:Dextrans; D006401:Hematologic Agents; D011239:Prednisolone; D010431:Pentoxifylline